SG Issue CW26 WuXi AppTec Warrant (23924)
Market Closed
HKEX HKEX Primary - Market Cap
- P/E Ratio
- Div Yield
- Volume
- Eps
HKD
Previous Close Want to track 23924 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
23924 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
23924 Chart
SG Issue CW26 WuXi AppTec Warrant (23924) FAQ
What is the stock price today?
The current price is 0.00 HKD.
On which exchange is it traded?
SG Issue CW26 WuXi AppTec Warrant is listed on HKEX.
What is its stock symbol?
The ticker symbol is 23924.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has SG Issue CW26 WuXi AppTec Warrant ever had a stock split?
No, there has never been a stock split.
SG Issue CW26 WuXi AppTec Warrant Profile
| Health Care Technology Industry | Healthcare Sector | - CEO | HKEX Exchange | - ISIN |
| Hong Kong Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
The SG Issue CW26 WuXi AppTec Warrant is a structured derivative product issued by Société Générale, functioning as a call warrant linked to the shares of WuXi AppTec, a prominent Chinese contract research, development, and manufacturing organization (CRDMO) in the pharmaceutical and biotechnology sectors. It grants investors the right, but not the obligation, to buy the underlying WuXi AppTec stock at a predetermined strike price on or before the expiration date in 2026, offering leveraged exposure to the company's performance. WuXi AppTec specializes in end-to-end services for drug discovery, development, and commercial manufacturing, serving global biopharma clients with a strong emphasis on small molecule APIs, biologics, and advanced therapies. Notable features include high effective gearing for amplified returns, a specified lot size, and moneyness indicating its out-of-the-money position, alongside liquidity provision metrics like transaction volume. This warrant plays a key role in the structured products market, enabling retail and institutional investors to speculate on or hedge against movements in WuXi AppTec's stock amid geopolitical scrutiny from U.S. legislation like the BIOSECURE Act and the company's robust order backlog exceeding 43 billion yuan.
Contact Information
Address: -
Phone: -
